Tarsus Pharmaceuticals, Inc.
TARS
$58.85
$2.243.96%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 295.52M | 233.67M | 182.95M | 129.62M | 83.37M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 295.52M | 233.67M | 182.95M | 129.62M | 83.37M |
| Cost of Revenue | 78.62M | 72.11M | 66.21M | 58.93M | 56.05M |
| Gross Profit | 216.90M | 161.56M | 116.74M | 70.69M | 27.33M |
| SG&A Expenses | 314.95M | 270.73M | 237.31M | 211.29M | 183.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 393.57M | 342.84M | 303.52M | 270.22M | 239.75M |
| Operating Income | -98.05M | -109.17M | -120.57M | -140.60M | -156.37M |
| Income Before Tax | -91.99M | -104.94M | -115.55M | -134.34M | -150.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -91.99 | -104.94 | -115.55 | -134.34 | -150.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.99M | -104.94M | -115.55M | -134.34M | -150.07M |
| EBIT | -98.05M | -109.17M | -120.57M | -140.60M | -156.37M |
| EBITDA | -96.42M | -107.75M | -119.34M | -139.46M | -155.27M |
| EPS Basic | -2.33 | -2.73 | -3.10 | -3.81 | -4.48 |
| Normalized Basic EPS | -1.43 | -1.65 | -1.87 | -2.31 | -2.72 |
| EPS Diluted | -2.33 | -2.73 | -3.10 | -3.81 | -4.48 |
| Normalized Diluted EPS | -1.43 | -1.65 | -1.87 | -2.31 | -2.72 |
| Average Basic Shares Outstanding | 158.65M | 154.11M | 150.07M | 143.45M | 135.69M |
| Average Diluted Shares Outstanding | 158.65M | 154.11M | 150.07M | 143.45M | 135.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |